Monoclonal antibody therapeutics is one of the fastest growing areas in the pharmaceutical industry because of the advantages including higher safety, efficacy and lower development cost. Discovery of novel target proteins for such therapy can provide great opportunities to improve therapeutic strategies for unmet medical needs. In this seminar, proteomic discovery platform for identifying potential oncology target proteins will be discussed with the colorectal cancer (CRC) program as an example. This includes quantitative measurement of the expression level of cell surface proteins and identification of the proteins expressed exclusively on CRC cells. Biological validation of the potential target proteins identified by this platform will be also discussed.
This work is based on the proteomics platform of Celera.
Further information:
P1-type ATPases are specific ATP driven pumps which transport soft heavy metals (Cu, Zn, Pb, Cd.) across the cell membranes. These large membrane proteins are difficult to purify and crystallize so that their complete structure is not known. We were interested in the structure and dynamics of the transmembrane part of the Cadmium ATPase (CADA) and the metal binding domains of the human Copper transporting ATPases like Menkes ATPase which takes the metal from the partner metallochaperones.
About the Speaker:
Dr. Karthik Arumugam received his PhD in Bioinformatics and Biophysics at the CEA (“Commissariat à l’énergie Atomique”), based in Grenoble (France), and wrote his thesis on the subject of Structure prediction and molecular dynamics simulation in transmembrane protein and GPCR protein. He joined the laboratory of Retrovirology as a post-doctoral researcher in bio-informatics. His work focuses now in the 3-dimensional structure prediction of the GPCR receptors CCR5 and CXCR4 which are the main co-receptors of HIV-1